What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Surgery, Chemotherapy, Oncology and Gastroenterology are his primary areas of study.
His study in Carcinoma, Combination chemotherapy, Bevacizumab, Lymphoma and Clinical endpoint is carried out as part of his studies in Internal medicine.
His work carried out in the field of Surgery brings together such families of science as Hazard ratio, Cancer and Rituximab.
John D. Hainsworth has included themes like Regimen and Anesthesia in his Chemotherapy study.
His work is dedicated to discovering how Oncology, Clinical trial are connected with Randomized controlled trial and other disciplines.
John D. Hainsworth combines subjects such as Neutropenia, Refractory, Performance status and Antimetabolite with his study of Gastroenterology.
His most cited work include:
- BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER (9191 citations)
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (3027 citations)
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy (2853 citations)
What are the main themes of his work throughout his whole career to date?
John D. Hainsworth spends much of his time researching Internal medicine, Oncology, Surgery, Chemotherapy and Gastroenterology.
Regimen, Carboplatin, Lung cancer, Bevacizumab and Toxicity are the core of his Internal medicine study.
As a member of one scientific family, he mostly works in the field of Oncology, focusing on Metastatic breast cancer and, on occasion, Trastuzumab.
The concepts of his Surgery study are interwoven with issues in Cancer and Rituximab.
Within one scientific family, he focuses on topics pertaining to Carcinoma under Chemotherapy, and may sometimes address concerns connected to Adenocarcinoma.
His Gastroenterology research is multidisciplinary, relying on both Survival rate, Progressive disease and Leukopenia.
He most often published in these fields:
- Internal medicine (78.79%)
- Oncology (56.62%)
- Surgery (35.73%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (78.79%)
- Oncology (56.62%)
- Surgery (35.73%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Surgery, Phases of clinical research and Breast cancer.
His study ties his expertise on Gastroenterology together with the subject of Internal medicine.
His research in Oncology intersects with topics in Carboplatin, Regimen, Prostate cancer and Toxicity.
John D. Hainsworth interconnects Urology, Follicular lymphoma, Everolimus and Rituximab in the investigation of issues within Surgery.
His studies deal with areas such as Vincristine, Cyclophosphamide and Hazard ratio as well as Rituximab.
His work deals with themes such as Sunitinib and Renal cell carcinoma, which intersect with Bevacizumab.
Between 2012 and 2021, his most popular works were:
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (385 citations)
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study (333 citations)
- Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute (196 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
John D. Hainsworth mainly focuses on Internal medicine, Oncology, Surgery, Clinical endpoint and Bevacizumab.
His Internal medicine study deals with Gastroenterology intersecting with Everolimus.
His biological study spans a wide range of topics, including Chemotherapy, Pertuzumab, Trastuzumab, Adverse effect and Carcinoma.
The Paclitaxel research John D. Hainsworth does as part of his general Surgery study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His Bevacizumab research is multidisciplinary, incorporating elements of Disease progression and Response Evaluation Criteria in Solid Tumors.
His Prostate cancer research incorporates themes from Docetaxel and Urology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
